Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Apyx Medical CorporationNASDAQ: APYX
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items grows, but more slowly than its trailing trend
Q1 FY2026 other non-cash items of $545K rose 104.9% year over year, behind the +118.8% change in trailing-twelve-month other non-cash items. Sequentially, it fell 24.8% from the prior quarter. Over 3 fiscal years it compounded at +48.1% a year.
Context
- Other non-cash items amounted to 3.9% of revenue in FY2025, down 0.6 pp from a year earlier.
- Other non-cash items increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +104.9% toward the trailing-twelve-month pace of +118.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- 2.04M USD
- Year-over-year change
- -4.9%
- 4-year CAGR
- +35.6%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.04M | -4.9% |
| FY2024 | 2024-12-31 | 2.15M | -4.8% |
| FY2023 | 2023-12-31 | 2.25M | +258.6% |
| FY2022 | 2022-12-31 | 628K | +4.1% |
| FY2021 | 2021-12-31 | 603K | — |
Other Non-Cash Items vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 other non-cash items of $2.83M is the 5th largest of the 8 companies compared; the peer median is $2.82M.
- Its year-over-year change of +118.8% is the 5th highest of 8, against a peer median of +324.3%.
- Other non-cash items amounts to 5.1% of revenue for APYX, versus a peer median of 10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.91B | +161769.7% | +139.5% | 465745.8% | |
| LTM Mar 2026 | $6.1M | +356.2% | +37.7% | 8.2% | |
| LTM Mar 2026 | $4.13M | +324.3% | +55.0% | 12.0% | |
| LTM Mar 2026 | $3.34M | +84.6% | +25.7% | 4.6% | |
| LTM Mar 2026 | $2.83M | +118.8% | +48.1% | 5.1% | |
| LTM Mar 2026 | $2.82M | +33.8% | +4.4% | 2.3% | |
| LTM Mar 2026 | $699K | +677.7% | +55.5% | 1226.3% | |
| LTM Mar 2026 | $125K | -60.3% | — | — | |
| Peer median (excluding APYX) | $2.82M | +324.3% | +46.3% | 10.1% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (15.2M) | (23.28M) | (18.85M) | (23.56M) | (11.11M) |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.09M | 6.7M | 5.11M | 4.01M | 2M |
| Change in Working Capital | (1.84M) | (5.22M) | 5.54M | (1.25M) | (1.59M) |
| Accounts Receivables | (4.9M) | 1.92M | 3.97M | (2.04M) | (1.32M) |
| Inventory | (2.86M) | (5.57M) | 1.46M | 2.26M | (1.07M) |
| Accounts Payables | 1.15M | 67K | 25K | (63K) | 355K |
| Other Working Capital | 4.76M | (1.63M) | 88K | (1.41M) | 446K |
| Other Non-Cash Items | 603K | 628K | 2.25M | 2.15M | 2.04M |
| Operating Cash Flow | (10.45M) | (20.28M) | (5.25M) | (18.05M) | (8M) |
| Capital Expenditures | (723K) | (1.01M) | (533K) | (722K) | (1.11M) |
| Acquisitions (Net) | 195K | 0 | 7.41M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (195K) | 0 | (147K) | 0 | 0 |
| Investing Cash Flow | (723K) | (1.01M) | 6.73M | (722K) | (1.11M) |
| Debt Repayment | (238K) | (148K) | 35.04M | (20K) | (20K) |
| Common Stock Issued | 67K | 365K | 2.72M | 7M | 9.54M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 195K | 0 | (5.59M) | (235K) | 60K |
| Financing Cash Flow | 24K | 217K | 32.17M | 6.75M | 9.58M |
| Effect of Forex Changes | 103K | 395K | (191K) | 113K | (466K) |
| Net Change in Cash | (11.05M) | (20.68M) | 33.46M | (11.91M) | (1K) |
| Free Cash Flow | (11.17M) | (21.29M) | (5.78M) | (18.77M) | (9.12M) |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.